Q/C Technologies, Inc.

QCLS
$3.85 (- $0.11 - 2.78%)
Last updated: 2026-07-04 19:33 UTC
QCLS Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorTechnology
IndustryComputer Hardware
ISINUS62856X3008
CUSIP62856X300
Market Price3.85
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-116.64
Market Cap$21.4M
Book Value4.76
Price to Book1.078
Beta2.25
52w High152.0
52w Low2.5
Next Earnings DateN/A

Q/C Technologies, Inc. trades under ticker QCLS on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Technology exposure. Identifiers: ISIN US62856X3008, CUSIP 62856X300.

About the Company
Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. The company has a strategic alliance with DADA2 Foundation for research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
Price History